Involvement of microRNAs in the inflammatory pathways of pulmonary sarcoidosis by unknown
INTRODUCTION
Sarcoidosis (also known as Besnier-Boeck-Schaumann
disease) is a chronic, multi-organ disorder of unknown etiology.
It is characterized by formation of non-necrotizing granulomas
in different organs, what leads to their damage or dysfunction. In
more than 90% of cases systemic sarcoidosis affects lungs and
mediastinal lymph nodes. Extrapulmonary involvement usually
concerns skin, peripheral lymph nodes, salivary glands, eyes,
central and peripheral nervous system. Granulomas’ formation
in the bone marrow leads to severe hematological disorders,
while cardiac involvement affecting up to 30% of sarcoidosis
patients can lead to severe cardiac complications (conduction
abnormalities, ventricular arrhythmias, progressive heart failure)
(1). Unfortunately, cardiac involvement in patients with
sarcoidosis is difficult to diagnose. Therefore, the physicians
must keep a high index of suspicion in order to immediately
introduce the life-saving treatment. The disease most often
occurs in adults aged 25 to 40 years old. Symptoms depend on
the affected organ and the most common are shortness of breath,
cough, fatigue, fever, pain in the joints, erythema nodosum,
anergy and - in the advanced stage of pulmonary involvement -
sarcoidosis-associated pulmonary hypertension (SAPH) (2-4).
The course of the disease can be either acute or chronic.
Since no single agent responsible for the development of
the disease was characterized so far, diagnosis of sarcoidosis is
based on medical examination and exclusion of other diseases.
Chest x-ray pictures may reveal sarcoid granulomas in the
lungs and enlarged chest lymph nodes. Further
histopathological analysis, high-resolution computed
tomography (HRCT), [18F] fluorodeoxyglucose positron
emission tomography (FDG-PET) or magnetic resonance
imagining (MRI) can be useful to confirm the disease (4, 5).
The most important step is the biopsy of invaded organs. As it
is crucial to distinguish sarcoidosis from other granulomatous
diseases like lymphoma, tuberculosis and tumors, non-
necrotizing granulomas should be identified in more than one
organ with concomitant exclusion of any other diseases (2, 3).
Modern strategy for diagnosis of mediastinal lymphadenopathy
involves less invasive procedures than in past years.
Endobronchial ultrasound-guided transbronchial needle
aspiration (EBUS-TBNA) is a key diagnostic tool to obtain
cytological specimens from enlarged mediastinal lymph nodes
(6-8). Endobronchial biopsy of mucosa and transbronchial lung
biopsy provide additional diagnostic yield to EBUS-TBNA.
Another very common and useful procedure is bronchoalveolar
lavage (BAL) fluid investigation. Evaluation of a percentage of
lymphocytes and CD4/CD8 ratio in BAL fluid, as well as the
level of different biomarkers in BAL fluid and serum such as
neopterin, soluble IL-2 receptor, tumor necrosis factor-α
(TNF-α), C-reactive protein (CRP), monocyte chemotactic
protein (MCP-1), macrophage inflammatory protein 1α (MIP-
1α) or angiotensin-converting enzyme (ACE) may help to
distinguish sarcoidosis from other diseases including non-
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sarcoidosis interstitial lung disease (2, 3). However, due to low
specificity and sensitivity, measurement of concentration of the
abovementioned molecules in serum does not prove to be an
effective method for confirmation of the disease and has little
clinical significance (5). Also, the level of these factors as well
as other cytokines and chemokines could vary significantly
depending on ethnic background (Caucasian, African-
American and Asian) (3, 9, 10), immunological and disease
status. Finally, expert clinician assessment is needed to reach a
final diagnosis.
MOLECULAR PLAYERS IN GRANULOMA FORMATION
The non-necrotizing granulomas, appearing in numerous
organs, consist mostly of tissue macrophages, CD4+ T helper 1
(Th1) lymphocytes and multinucleate giant cells (4). The giant
cell is made up of many macrophages that fuse together and is
seen in the central region of the granuloma. Study of
neuromuscular sarcoidosis shows that tissue macrophages are
polarized into M2 phenotype (11). In the early phase of immune
response follicular hyperplasia and sinus histiocytosis are
similar to the symptoms of non-specific granulomatous
lymphadenitis (12). Later, small epithelioid nodules appear
within the node. In the peak phase the granulomas are clearly
visible in the lymph nodes while in the late phase the collagen
fibers may be produced, resulting in granulomas fibrosis and
hyalinization (12, 13).
Moller and Chen suggested that the key element in the
pathogenesis of sarcoidosis is the interaction between major
histocompatibility complex - MHC (alias human leukocyte
antigen - HLA) class II on antigen-presenting cell (APC),
antigen and T-cell receptor (TCR) on CD4+ T cell (14) (Fig. 1).
This provides the first activation signal for antigen-specific T
cells. The second signal provided by costimulatory molecules
stimulates T cells to produce cytokines that orchestrate immune
responses leading to granuloma formation.
According to that, the HLA class II gene alleles strongly
determine the clinical outcome, such as progression and severity
of the disease. Many other groups have also indicated that some
of the alleles of HLA genes may increase the risk of developing
the disease (9, 10, 15, 16). Genome-wide analysis by Shurmann
et. al. has shown that loci heterogeneity in MHC region as well
as in some minor genes located on chromosomes 1, 3, 7, 9 and
X are associated with susceptibility to sarcoidosis (17). Others
have suggested different genome regions as potentially
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Fig. 1. Hypothetical model of the immunopathogenesis of sarcoidosis. Mycobacterial antigens released upon mycobacterial infection
induce the macrophage- and neutrophil-dependent innate immune response. Host proteins (particularly serum amyloid A, SAA)
induced as part of this response aggregate with a mycobacterial protein catalase peroxidase (mKatG). Macrophages and dendritic cells
(antigen-presenting cells, APC), activated by mKatG, host protein SSA and their aggregates, produce the helper T cell type 1 (Th1)-
promoting cytokines IL-2, IL-12, IL-18, TNF-α, and IFN-γ. Antigen-specific Th1 responses orchestrate the complex process of
granuloma formation and accompanying inflammation. Removal of mKatG, SAA and mKatG-SAA aggregates results in granuloma
regression and disease remission. Failure to remove them results in persistent inflammation and chronic disease.
significant in the disease etiology, among which: 5p, 5q, 12p,
11p, 20q, 9q, 1p and 2p were identified (18, 19). A significant
association was reported in German population between
sarcoidosis and polymorphism in the butyrophilin-like 2
(BTNL2) gene (rs2076530 A allele) (20). BTNL2 is a member of
the immunoglobulin gene family that functions to inhibit T cell
activation (21).
Additionally, it has been recently discovered that serum
amyloid A (SAA) protein regulates granulomatous inflammation
through Toll-like receptor 2 (TLR-2) (22) (Fig. 1). TLR-2 is a
membrane protein that is expressed on the surface of phagocytic
cells: microglia, Schwann cells, monocytes, macrophages,
dendritic cells (DC) as well as T and B cells. Interaction between
SAA protein and TLR-2 initiates cytokine release, intensifying
the immune response. It has also been proven that the level of
that serum protein may indicate disease progression (23). Other
publications report on the significance of TLR-9 in pulmonary
sarcoidosis (24, 25). The involvement of TLR-9 indicate the
recognition of intracellular patterns, which is characteristic for
autoimmune diseases. On the other hand, Mycobacterium
tuberculosis, a putative infectious agent linked to sarcoidosis
pathogenesis (Fig. 1), can activate TLR-9. It was shown that
mice lacking both TLR9 and TLR2 were significantly more
susceptible to M. tuberculosis infection than mice with single
deficiency of either TLR2 or TLR9 (26). This indicates a
significant role for TLR9 and its cooperation with TLR2 in host
defense to mycobacterial infection.
IMMUNE CELLS INTERPLAY
IN SARCOID GRANULOMA
Granulomas consist of two distinguishable layers: an
epithelioid core and surrounding, peripheral layer of infiltrated
lymphocytes - in which there are CD4+ and CD8+ cells,
regulatory T lymphocytes, B lymphocytes, macrophages and
DCs (27, 28). The importance of DCs in the generation of
sarcoid granulomas has been pointed out in several studies.
These cells act as professional APCs with the ability to
influence T cell activation and differentiation. While, based on
flow cytometry, myeloid DCs are just about 1% of all BAL
fluid cells, during inflammation their number significantly
increases in lung alveolar space compared to alveolar
macrophages (29). Importantly, DCs in sarcoidosis do not
mature in the lung and skin, but they do mature in the lymph
node (29). Mature DCs possess the ability to activate both
naive and effector T cells (30). TNF-α produced by
inflammatory DCs encourages CD4+ T cell proliferation and
survival, both indirectly by inducing DCs maturation into APC
and directly through the induction of the T cell IL-2 receptor
(IL-2R) (30). Many research groups have described the
significance of TNF-α within granulomas (31-33).
Shifting the balance of Th cells into Th1 phenotype in
sarcoidosis leads to increased production of IFN-γ, IL-2, IL-12,
IL-18, and TNF-α within the granuloma (29) (Fig. 1). Th1
character of the granuloma-infiltrating T-lymphocytes was
additionally confirmed by bioinformatic analysis, as the
signaling network associated with sarcoidosis, was found to be
regulated by signal transducer and activator of transcription-1
(STAT1) - the molecule located downstream of IFN-γ receptor in
cell signaling pathways (34, 35). However, it is still unclear how
this phenomenon contributes to the formation of these non-
necrotizing structures. Possibly, interaction between Th1 cells
and another T lymphocyte subpopulation (Th17) that invade
granulomas is the key factor for their maintenance (36, 37).
Other cells, which seem to play an important role in the
prolonged inflammation and granuloma formation in
sarcoidosis, are T regulatory (Treg) lymphocytes. These cells,
defined as CD4+CD25+FoxP3+ cells, accumulate at the periphery
of the sarcoid granuloma (Fig. 1), are present in the BAL fluid
and peripheral blood of sarcoidosis patients. It has been
demonstrated that Treg cells from sarcoidosis patients inhibit
proliferation of effector T lymphocytes independently of their
origin (peripheral blood, BAL fluid or lymph nodes) (28, 38).
This antiproliferative activity of Treg cells may be the cause of
peripheral CD4+ T helper cells anergy noted in sarcoidosis.
Majority of Treg cells was found in patient’s lymph nodes,
where the T lymphocytes maturate. These cells may be also
responsible for the sustaining of granulomas’ formation (39).
What is more, different effect of Treg cells on inflammatory
cytokine secretion by effector T lymphocytes was demonstrated
in healthy people and patients with sarcoidosis (28). Unlike Treg
cells from healthy individuals, sarcoidosis regulatory
lymphocytes do not completely inhibit IFN-γ and TNF-α
production by effector T cells (28). They do, however, abolish
IL-2 production, an important cytokine promoting the
polarization of Th cells into Th1 phenotype. This regulatory
mechanism may be useful for future therapies. The modulation
of number/function of T reg lymphocytes could be an approach
to control the immunopathology of the disease (40).
PUTATIVE PATHOGENESIS
Despite the fact that the main antigen that triggers
sarcoidosis remains unknown, few pathogens are thought to
contribute to disease development. For example, mycobacterial
protein catalase peroxidase (mKatG) is a tissue antigen and a
target of the adaptive immune response in systemic sarcoidosis
(41-43) (Fig. 1). Moreover, mKatG is not the only molecule that
T cells respond to. A response of sarcoidosis patients’ Th1
lymphocytes against mycobacterial superoxide dismutase A
(SodA) or early secreted antigenic target 6 (ESAT-6) protein,
have also been reported (44). It is notable that unlike the cells
from BAL fluid, the peripheral blood mononuclear cells
(PBMCs) could not recognize these antigens. However, in a
different study it was proven that M. tuberculosis antigen 85A
can be recognized by Th1 cells from the circulation (45).
Furthermore, 4 peptides within antigen 85A have been
identified as immunogenic, thus may induce Th1 response in
sarcoidosis patients. Despite the confirmed
immunopathogenesis of M. tuberculosis, it is still not known
whether mycobacterial proteins may have an important role in
the activation of the immune response in sarcoidosis (45). Other
reports suggest that Propionibacterium acnes and
Propionibacterium granulosum may be the causative agents
(12). It is well known that P. acnes belong to human
microbiome and reside mainly in the skin, but could also be
present in the lymph nodes. Thus, the current understanding is
that multiple exogenous antigens are incriminated in the
pathogenesis of sarcoidosis.
Other hypothesis suggests that sarcoidosis is an
autoimmune disease. Since no single agent was found present in
the granulomas and none to be responsible for triggering the
immune response, it is suspected that sarcoidosis develops due
to dysfunction in the immune reactions. Previously mentioned
activation of TLR-9 supports this hypothesis. However, no
particular signaling pathway has been indicated as impaired or
inactive during the interaction between DCs, T lymphocytes,
and other leukocytes. The defect in immunoregulation may
affect either APCs or lymphocytes or both, however, it remains
to be elucidated whether the main cause concerns incorrect
signal transduction through the immunological synapse
between these cells.
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microRNAs IN THE IMMUNE RESPONSE
Small, non-coding RNA molecules of about 20 nt in length,
known as microRNAs (miRNAs) were shown to regulate
expression of 50 – 60% of genes in human genome using RNA
interference mechanism. A single miRNA molecule may
interfere with up to 100 mRNA molecules (46). These short
particles are coded in regions located both within introns of
protein-coding fragment (mirtrons) as well as outside of them.
Some miRNAs are grouped into so-called clusters - structures
that are coordinately transcribed, while others remain as distinct
units. Their expression is driven by RNA polymerase II, and
maturation is driven by two RNase III enzymes (Droscha and
Dicer), that modify primary transcript into final, regulatory
molecule. MicroRNAs’ binding to 3’ untranslated region (UTR)
of a transcript may result in decrease of stability by facilitation
of deadenylation or repression of translation, thus a functional
protein is not produced (46). It is important to note that these
effects do not require the sequence of miRNAs and mRNA to be
fully complementary. An RNA-induced silencing complex with
a specific miRNA within (miRISC), may block translation in the
process called miRNA-mediated mRNA decay, thus controlling
functionality of specific cells and tissues (46). Importance of
miRNA in embryonic development, cell differentiation and
proliferation, as well as in apoptosis and neoplasia has already
been described (47-51).
Although, the immune response is highly regulated at the level
of transcription, RNA interference plays a significant role in
mechanisms of both innate and adaptive immunity (52). The most
important molecules in the non-specific response are miR-9, miR-
146a and miR-155, as they regulate the activation of myeloid
cells. Targets of these miRNAs were proved to down-regulate
proteins of Toll-like and intereleukin-1 receptor (TIR) signaling
pathway. Among them there are: Fas-associated death domain
protein, IκB kinase ε (IKKε), receptor interacting serine-threonine
kinase 1 (Ripk1), TGF-β activated kinase 1/MAP3K7 binding
protein 2 (TAB2), nuclear factor-κB1 (NF-κB1), tumor necrosis
factor receptor-associated factor 6 (TRAF6) and IL-1 receptor
activated kinase-1 (IRAK1) (53-56). What is more, miR-155,
miR-223 and the miR-17 – 92 cluster are thought to regulate
myeloid cells’ proliferation and differentiation (57-59). As for the
acquired immune response, RNase III Dicer knockout mice
proved that miRNAs are crucial for T and B cell proliferation as
well as for development and immunosuppressive activity of Treg
lymphocytes (48, 60-64). It is essential to remember that despite a
great influence of these molecules onto protein biosynthesis, these
post-transcriptional regulators of translation depend on the
transcriptional content of the cells.
microRNAs IN SARCOIDOSIS
In the context of sarcoidosis it is important to determine if
the abnormalities in immune system are somehow connected to
the regulation of translation by miRNA molecules. Of note is
that FoxP3, a transcription factor needed for differentiation of T
cells into Treg lymphocytes, induces miR-155 expression which,
however, does not affect Treg immunosuppresive functions (65,
66). Also, miR-155 was shown to be required for the release of
cytokines such as IL-2 and IFN-γ by Th1 cells and in the case of
thymic differentiation it down-regulates the suppressor of
cytokine signaling 1 (SOCS1), a negative regulator of IL-2R
signaling, and regulates cells survival (67) (Fig. 2). Considering
the increased number of regulatory lymphocytes in patients’
blood and lymph nodes this molecule may be a possible target
for future therapies. Interestingly, it was found that miR-155
knock-out animals display a bias towards T helper 2 (Th2)
differentiation indicating that miR-155 promotes differentiation
into Th1 cells (67, 68). Another molecule miR-31, was shown to
inhibit T cell differentiation into T reg lymphocytes by binding
to a potential target site within 3’ UTR of FoxP3 mRNA and
down-regulate this protein synthesis (69) (Fig. 2).
Another key element regulating Treg cells is miR-146a,
whose deficiency, contrary to miR-155, results in increased
number of these cells, defect in their immunosuppressive
function and deregulated IFN-γ response (70). The disruption of
immunological tolerance manifests itself in IFN-γ-dependent
immune-mediated lesions in many organs, most possibly as an
effect of increased expression of STAT1. STAT1 is a key
transcription factor in IFN-γ response and a known target of
miR-146a (71). One of the reasons for increased expression of
STAT1 might be the downregulation of its mRNA degradation -
a result of the lack of miR-146a. Also, STAT1 activation in Treg
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Fig. 2. MicroRNA-mediated regulation of T cell development
and function - a flow chart showing the possible involvement of
miRNAs in the pathogenesis of sarcoidosis.
FoxP3 - the main regulator of T lymphocytes differentiation into
T regulatory cells, which can be blocked by miR-31, induces
miR-155 expression, which targets SOCS1, a negative regulator
of STAT1 signaling. In contrast - miR-146a, which can be
activated by IFN-γ, suppresses STAT1 and reduces the number
of Treg cells. SOCS1 is also a negative regulator of IL-2R
signaling and its inhibition by up-regulated miR-155 can
improve the Th1 cell survival. Consequently, a shift towards Th1
cells can happen in sarcoidosis.
cells with selective ablation of SOCS1, a negative regulator of
STAT1, resulted in similar Th1-mediated pathology (65). This
leads to the conclusion that an optimal level of STAT1 within the
cell is required for proper regulation of Th1 cells by Treg
lymphocytes (71). A signaling network between Tregs, Th1
cells, SOCS1, STAT1, IFN-γ, IL-2, miR-155 and miR-146a can
be important also in the context of sarcoidosis. Additionally,
miR-155 was shown to be one of the microRNAs that is
differentially expressed in M1 and M2 macrophages (72), which
play also part in the granuloma formation in sarcoidosis.
Lately, Crouser et al. conducted a microarray analysis of
lung tissue as well PBMCs of sarcoidosis patients and healthy
people in order to determine the level of various miRNA
molecules (73). As the results show, some regulatory RNA
expressions may be lowered or elevated in relation to the control
samples, depending on the origin of the cells. Bioinformatic
analysis of differentially expressed miRNAs has been performed
and molecular targets of identified factors have been predicted.
Despite the fact that profiles of miRNA expression in patients’
PBMCs and lung tissue do not overlap, in both cases the
predicted targets are within TGF-β/WNT pathways (73). It has
been observed, that higher TGF-β production correlates with
spontaneous regression of sarcoidosis (74). Also, this factor is
needed for the survival and expansion of T lymphocytes (75,
76). Interestingly, another study shows that TGF-β increases
miR-155 expression, but downregulates IL-2 and IFN-γ in CD4+
cells (77). This regulation, in the context of complete inhibition
of IL-2 in sarcoidosis patient cells, requires further investigation.
Two other papers suggested that pulmonary fibrosis, which is
observed in significant percentage of chronic sarcoidosis
patients, may be dependent on TGF-β gene variant (78, 79). On
the other hand, WNT signaling pathway, which is responsible for
T cells development, as well as Treg and DCs activation (80)
was shown to be activated in sarcoidosis (81).
Interestingly, a recent report presents a molecular-level
comparison of 2 pulmonary inflammatory diseases: sarcoidosis
and tuberculosis (82). Cytokine levels in patients serum and
miRNA expression in PBMCs were analyzed. Surprisingly, as
many mRNA transcripts and miRNA molecules from blood cells
were found to be expressed at similar level in both diseases.
Therefore, these two pathological conditions seem to share
common inflammatory underlying mechanisms. The molecule
miR-144, involved in the cellular response to oxidative stress,
was shown as the most strongly up-regulated factor in both
diseases in comparison to healthy controls (82). While
determining the presence of cytokines in sera the authors found
out that, in general, tuberculosis is characterized by higher
expression of pro-inflammatory cytokines (such as IFN-γ, IL-12)
while sarcoidosis sera contained lower concentration of
molecules mediating chemotaxis and stimulating granulocytes
(Chemokine (C-C motif) ligand 5, Chemokine (C-C motif) ligand
27, stem cell growth factor beta and leukemia inhibitory factor).
Also, in both cases transcriptional profiling of blood cells
revealed activation of common pro-inflammatory pathways. It
was suggested that pulmonary sarcoidosis is the closest matching
disease to active pulmonary tuberculosis (82).
Very recently our group has shown that PBMCs isolated
from sarcoidosis patients contained significantly higher level of
miR-34a than cells obtained from healthy individuals (83). This
molecule was previously found to be up-regulated in melanoma
cells stimulated with IFN-γ (84), a cytokine shown also to be
increased in sarcoidosis patients’ sera (83), lymph nodes (85)
and BAL fluid (86). MiR-34a was described as a tumor
suppressor that inhibits silent information regulator 1 (SIRT1).
SIRT1 downregulation leads to an increased level of acetylated
p53 and colon cancer cells apoptosis (87). Moreover, inhibition
of SIRT1 by miR-34a causes disruption in cellular energy
metabolism and stimulates the NF-κB-induced inflammatory
responses (88). Interestingly, recently it was shown that miR-34a
is induced following TCR-induced T cell activation and down-
regulates diacylglycerol kinase ζ (DGKζ) via its seed matches in
both coding region and 3’ UTR of DGKζ, resulting in enhanced
expression of T cell activation marker CD69 (89).
Although there has been substantial progress in understanding
the biochemical and molecular pathways involved in the
pathology of sarcoidosis over the past few years, several important
questions remain to be answered. First, is there only one key agent
leading to the disease progression? Second, what are the genes or
their variants that increase susceptibility to develop sarcoidosis
and shape the clinical outcome of the individual patient? However,
despite the incomplete understanding of disease mechanisms, the
diagnostic strategies of sarcoidosis have improved. Determining
the causes and populations at risk for the disease would not only
improve diagnosis and treatment, but possibly aid in prevention.
For that, further research on the molecular mechanisms of the
disease is needed. Intracellular gene expression, as well as, cell-to-
cell signaling should be studied deeper in order to build an
advanced model of etiology and immunopathogenesis. To achieve
that, it might be important to investigate the role of miRNAs in
regulation of specific cell’s transcriptome, such as the role in the
immune response and regulatory T cells.
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